Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Bispecific antibody

This page shows the latest Bispecific antibody news and features for those working in and with pharma, biotech and healthcare.

Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting

Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting

Polivy – a first-in-class anti-CD79b antibody-drug conjugate – is already available in relapsed or refractory DLBCL but Roche believes patients would benefit from a first-line indication. ... Roche will also present pivotal data showing that

Latest news

More from news
Approximately 5 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Unlocking the potential of precision medicine in oncology Unlocking the potential of precision medicine in oncology

    We are following a similar approach in lung cancer through an ongoing partnership to pursue a molecular diagnostic strategy for our early-stage investigational EGFR-MET bispecific antibody, which is being

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    In April last year, it achieved a very successful IPO on the US Nasdaq, generating $208m thanks to investor belief in its cancer-focused antibody-based pipeline. ... In addition to traditional antibodies, the pipeline also includes antibody drug

  • Deal Watch December 2016 Deal Watch December 2016

    5, 500. Merus Labs (Canada). Incyte (US). Discovery collaboration. Biclonics bispecific antibody technology for up to 11 research programmes, including 2 in immuno-oncology. ... Not disclosed. Bispecific antibody technology. Exicure. Purdue. $790m. Not

  • Deal Watch September 2016 Deal Watch September 2016

    The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... Pfizer acquired an exclusive licence to OncoImmune's

  • Deal Watch August 2016 Deal Watch August 2016

    469. Genmab (DK). Gilead (US). Licence. DuoBody technology platform to develop bispecific antibody candidates for targeting HIV plus option to second licence.

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

  • New hires at Crescendo, Healx and Galecto New hires at Crescendo, Healx and Galecto

    late phase clinical trials. Before that, he was clinical research physician at Chugai Pharma Europe, where he led clinical development for a bispecific T-cell engaging antibody programme and other early

  • New hires at FibroGen, Saniona and Turbine New hires at FibroGen, Saniona and Turbine

    Previously, she held the position of senior vice president of drug discovery at F-star, overseeing all internal and collaborative bispecific antibody discovery programmes.

  • F-star hires ex-BMS immuno-oncology leader

    Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... Hewill oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent

  • F-star appoints GSK's Neil Brewis F-star appoints GSK's Neil Brewis

    Cambridge-based antibody research company F-Star has appointed Dr Neil Brewis as chief scientific officer. . ... This appointment strengthens our experienced management team and supports F-star's strategy to lead the bispecific antibody space in

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...

Quick links